Ticker
ADMP

Price
0.34
Stock movement up
+0.00 (0.50%)
Company name
Adamis Pharma
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Markedsverdi
50.87M
Ent verdi
47.76M
Pris/omsetning
4.79
Pris/bok
3.20
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-69.44%
3 års avkastning
-29.62%
5 års avkastning
-42.18%
10 års avkastning
-27.99%
Sist oppdatert: 2022-08-25

UTBYTTE

ADMP betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning4.79
Pris til bok3.20
EV i forhold til salg4.50

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall149.98M
EPS (TTM)-0.12
FCF per aksje (TTM)-0.24

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)10.62M
Bruttofortjeneste (TTM)903.48K
Driftsinntekter (TTM)-34.29M
Netto inntekt (TTM)-17.79M
EPS (TTM)-0.12
EPS (1 år fremover)-0.05

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)8.51%
Driftsmargin (TTM)-322.78%
Fortjenestemargin (TTM)-167.50%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter17.77M
Netto fordringer4.60M
Samlede omløpsmidler27.79M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler30.55M
Leverandørgjeld4.89M
Kortsiktig/nåværende langsiktig gjeld2.46M
Sum kortsiktig gjeld13.58M
Sum gjeld14.65M
Aksjonærenes egenkapital15.90M
Netto varige driftsmidler15.90M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-47.28M
Kapitalutgifter (TTM)1.11M
Fri kontantstrøm (TTM)-36.08M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-111.90%
Avkastning på eiendeler-58.24%
Avkastning på investert kapital-109.45%
Kontantavkastning på investert kapital-221.94%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning0.34
Daglig høy0.34
Daglig lav0.33
Daglig volum249K
Tidenes høyeste1835.63
1 år analytikerestimat0.42
Beta1.19
EPS (TTM)-0.12
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon21 Nov 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
ADMPS&P500
Nåværende prisfall fra toppnotering-99.98%-12.18%
Høyeste prisfall-99.98%-56.47%
Dato for høyeste fall22 Aug 20229 Mar 2009
Gj.snittlig fall fra topp-79.93%-11.38%
Gj.snittlig tid til ny topp247 days12 days
Maks tid til ny topp5606 days1805 days
SELSKAPSOPPLYSNINGER
ADMP (Adamis Pharma) company logo
Markedsverdi
50.87M
Markedsverdi kategori
Small-cap
Beskrivelse
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Ansatte
15
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Dennis J. Carlo
Land
USA
By
San Diego
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infe...
21. september 2022
Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Indep...
21. september 2022
The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects Independent Data Monitoring Board to review interim data from approximately 200 initial subjects SAN DIEGO, Sept...
12. september 2022
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announce...
12. august 2022
Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ETSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopha...
10. august 2022
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdo...
8. august 2022
ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on Aug...
29. juli 2022
Interim DSMB review expected in late SeptemberSAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phas...
29. juli 2022
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdo...
21. juli 2022
Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
31. mai 2022
Neste side